| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Psoriasis | 160 | 2025 | 254 | 32.430 |
Why?
|
| Dermatologic Agents | 41 | 2025 | 77 | 8.320 |
Why?
|
| Antibodies, Monoclonal, Humanized | 71 | 2025 | 1001 | 7.470 |
Why?
|
| Antibodies, Monoclonal | 53 | 2021 | 1395 | 6.740 |
Why?
|
| Interleukin-23 | 20 | 2024 | 60 | 4.900 |
Why?
|
| Biological Products | 16 | 2024 | 178 | 4.640 |
Why?
|
| Arthritis, Psoriatic | 19 | 2025 | 36 | 4.260 |
Why?
|
| Severity of Illness Index | 80 | 2025 | 1917 | 3.720 |
Why?
|
| Adalimumab | 25 | 2020 | 92 | 3.140 |
Why?
|
| Ustekinumab | 19 | 2022 | 52 | 2.770 |
Why?
|
| Interleukin-17 | 9 | 2024 | 109 | 2.750 |
Why?
|
| Double-Blind Method | 57 | 2025 | 1729 | 2.680 |
Why?
|
| Treatment Outcome | 86 | 2025 | 9099 | 2.640 |
Why?
|
| Quality of Life | 29 | 2025 | 1780 | 2.060 |
Why?
|
| Th17 Cells | 3 | 2024 | 93 | 1.610 |
Why?
|
| Interleukin-12 | 13 | 2023 | 108 | 1.590 |
Why?
|
| Humans | 181 | 2025 | 93515 | 1.450 |
Why?
|
| Skin Diseases | 7 | 2020 | 174 | 1.360 |
Why?
|
| Adult | 90 | 2025 | 27918 | 1.320 |
Why?
|
| Tumor Necrosis Factor-alpha | 19 | 2024 | 688 | 1.310 |
Why?
|
| Immunologic Factors | 9 | 2014 | 176 | 1.300 |
Why?
|
| Middle Aged | 90 | 2025 | 27573 | 1.220 |
Why?
|
| Dermatology | 5 | 2025 | 46 | 1.180 |
Why?
|
| Methotrexate | 10 | 2024 | 225 | 1.120 |
Why?
|
| Male | 100 | 2025 | 44557 | 1.110 |
Why?
|
| Immunoglobulin G | 14 | 2018 | 464 | 1.050 |
Why?
|
| Recombinant Fusion Proteins | 9 | 2008 | 555 | 1.040 |
Why?
|
| Female | 100 | 2025 | 48702 | 1.020 |
Why?
|
| Drug Administration Schedule | 18 | 2025 | 829 | 0.950 |
Why?
|
| Receptors, Tumor Necrosis Factor | 13 | 2011 | 83 | 0.940 |
Why?
|
| Interleukin-23 Subunit p19 | 3 | 2019 | 8 | 0.920 |
Why?
|
| Rheumatology | 1 | 2025 | 39 | 0.880 |
Why?
|
| Patient Reported Outcome Measures | 5 | 2020 | 283 | 0.880 |
Why?
|
| Piperidines | 4 | 2020 | 165 | 0.880 |
Why?
|
| Pyrroles | 3 | 2019 | 165 | 0.860 |
Why?
|
| Anti-Inflammatory Agents | 6 | 2019 | 353 | 0.830 |
Why?
|
| Withholding Treatment | 4 | 2019 | 121 | 0.830 |
Why?
|
| Arthritis, Rheumatoid | 5 | 2019 | 183 | 0.810 |
Why?
|
| Pyrimidines | 4 | 2020 | 384 | 0.800 |
Why?
|
| Chronic Disease | 15 | 2023 | 960 | 0.770 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2022 | 249 | 0.730 |
Why?
|
| Immunosuppressive Agents | 10 | 2019 | 990 | 0.690 |
Why?
|
| Anxiety | 3 | 2020 | 337 | 0.670 |
Why?
|
| Hidradenitis Suppurativa | 2 | 2019 | 13 | 0.660 |
Why?
|
| Skin Neoplasms | 11 | 2020 | 620 | 0.660 |
Why?
|
| Liver Diseases | 5 | 2020 | 243 | 0.650 |
Why?
|
| Clinical Trials as Topic | 5 | 2021 | 1103 | 0.640 |
Why?
|
| Dose-Response Relationship, Drug | 17 | 2018 | 1914 | 0.630 |
Why?
|
| Depression | 6 | 2020 | 544 | 0.630 |
Why?
|
| Uveitis | 2 | 2019 | 35 | 0.610 |
Why?
|
| Thalidomide | 5 | 2024 | 55 | 0.600 |
Why?
|
| Interleukins | 1 | 2019 | 133 | 0.570 |
Why?
|
| Etanercept | 15 | 2019 | 34 | 0.560 |
Why?
|
| Injections, Subcutaneous | 10 | 2025 | 131 | 0.540 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2022 | 920 | 0.520 |
Why?
|
| Biological Therapy | 4 | 2020 | 46 | 0.520 |
Why?
|
| TYK2 Kinase | 3 | 2022 | 7 | 0.510 |
Why?
|
| Immunotherapy | 5 | 2023 | 761 | 0.500 |
Why?
|
| Drug Substitution | 3 | 2024 | 28 | 0.470 |
Why?
|
| Maintenance Chemotherapy | 4 | 2020 | 91 | 0.460 |
Why?
|
| Placebos | 9 | 2019 | 206 | 0.460 |
Why?
|
| T-Lymphocytes | 10 | 2007 | 1275 | 0.450 |
Why?
|
| Aged | 36 | 2023 | 20434 | 0.420 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2011 | 202 | 0.410 |
Why?
|
| Crohn Disease | 3 | 2019 | 808 | 0.400 |
Why?
|
| Candidiasis, Oral | 2 | 2024 | 4 | 0.400 |
Why?
|
| Antibodies, Blocking | 1 | 2013 | 22 | 0.390 |
Why?
|
| Phototherapy | 5 | 2019 | 34 | 0.390 |
Why?
|
| Colitis, Ulcerative | 2 | 2019 | 800 | 0.380 |
Why?
|
| Heterocyclic Compounds | 3 | 2023 | 19 | 0.370 |
Why?
|
| Bowen's Disease | 3 | 1997 | 9 | 0.360 |
Why?
|
| Cross-Over Studies | 5 | 2020 | 390 | 0.360 |
Why?
|
| Time Factors | 14 | 2025 | 5410 | 0.360 |
Why?
|
| Adolescent | 17 | 2024 | 9606 | 0.340 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2014 | 603 | 0.310 |
Why?
|
| Keratolytic Agents | 3 | 2008 | 4 | 0.310 |
Why?
|
| Aged, 80 and over | 11 | 2020 | 7061 | 0.300 |
Why?
|
| Retreatment | 4 | 2017 | 104 | 0.300 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2019 | 289 | 0.300 |
Why?
|
| PUVA Therapy | 4 | 2009 | 24 | 0.290 |
Why?
|
| Pruritus | 6 | 2020 | 30 | 0.290 |
Why?
|
| Follow-Up Studies | 11 | 2019 | 3830 | 0.280 |
Why?
|
| Risk Assessment | 9 | 2018 | 2441 | 0.260 |
Why?
|
| Recurrence | 3 | 2019 | 1190 | 0.260 |
Why?
|
| Young Adult | 11 | 2023 | 6930 | 0.250 |
Why?
|
| Skin | 8 | 2025 | 578 | 0.250 |
Why?
|
| Nail Diseases | 2 | 2025 | 8 | 0.240 |
Why?
|
| Cardiovascular Diseases | 8 | 2019 | 754 | 0.240 |
Why?
|
| Patient Education as Topic | 3 | 2020 | 373 | 0.230 |
Why?
|
| Langerhans Cells | 1 | 2005 | 17 | 0.230 |
Why?
|
| Epidermis | 2 | 2005 | 103 | 0.230 |
Why?
|
| Cyclosporine | 6 | 2020 | 241 | 0.230 |
Why?
|
| Receptors, Interleukin | 1 | 2025 | 38 | 0.230 |
Why?
|
| Drug Eruptions | 2 | 1996 | 34 | 0.230 |
Why?
|
| Prognosis | 5 | 2018 | 3911 | 0.220 |
Why?
|
| Autoimmune Diseases | 2 | 1998 | 255 | 0.220 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2012 | 1077 | 0.220 |
Why?
|
| Carcinoma, Basal Cell | 4 | 2012 | 63 | 0.220 |
Why?
|
| Inflammatory Bowel Diseases | 5 | 2024 | 646 | 0.220 |
Why?
|
| Metabolic Syndrome | 4 | 2019 | 122 | 0.210 |
Why?
|
| Graft vs Host Disease | 1 | 2007 | 365 | 0.210 |
Why?
|
| Autoantibodies | 2 | 2003 | 277 | 0.210 |
Why?
|
| Patient Advocacy | 1 | 2005 | 63 | 0.210 |
Why?
|
| Consensus | 3 | 2024 | 368 | 0.210 |
Why?
|
| Health Care Costs | 2 | 2016 | 251 | 0.210 |
Why?
|
| Delphi Technique | 2 | 2018 | 135 | 0.210 |
Why?
|
| Laser Therapy | 2 | 1996 | 151 | 0.200 |
Why?
|
| Certolizumab Pegol | 2 | 2020 | 19 | 0.200 |
Why?
|
| Treatment Failure | 1 | 2024 | 292 | 0.200 |
Why?
|
| Clinical Trials, Phase III as Topic | 6 | 2024 | 165 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 1053 | 0.200 |
Why?
|
| Terminology as Topic | 1 | 2005 | 218 | 0.200 |
Why?
|
| Hand Dermatoses | 2 | 2020 | 8 | 0.200 |
Why?
|
| Biomarkers | 3 | 2021 | 1910 | 0.200 |
Why?
|
| ROC Curve | 2 | 2016 | 775 | 0.190 |
Why?
|
| Erythema | 2 | 2020 | 31 | 0.190 |
Why?
|
| Incidence | 4 | 2018 | 1701 | 0.190 |
Why?
|
| Disease Management | 1 | 2025 | 358 | 0.190 |
Why?
|
| Dermatitis, Atopic | 1 | 2023 | 65 | 0.180 |
Why?
|
| Patients | 1 | 2023 | 103 | 0.180 |
Why?
|
| Arthralgia | 2 | 2019 | 41 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 1 | 2024 | 304 | 0.180 |
Why?
|
| Macrolides | 1 | 2001 | 30 | 0.180 |
Why?
|
| Liver Cirrhosis | 2 | 2020 | 273 | 0.180 |
Why?
|
| Syringes | 1 | 2021 | 14 | 0.170 |
Why?
|
| Jaundice | 2 | 2020 | 14 | 0.170 |
Why?
|
| Sunscreening Agents | 1 | 2001 | 10 | 0.170 |
Why?
|
| Administration, Oral | 3 | 2018 | 657 | 0.170 |
Why?
|
| Mental Health | 2 | 2019 | 188 | 0.160 |
Why?
|
| Photochemotherapy | 2 | 2019 | 100 | 0.160 |
Why?
|
| Xanthomatosis | 1 | 2020 | 5 | 0.160 |
Why?
|
| Anticarcinogenic Agents | 1 | 2001 | 71 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2003 | 481 | 0.160 |
Why?
|
| Hemochromatosis | 1 | 2020 | 12 | 0.160 |
Why?
|
| Tacrolimus | 1 | 2001 | 372 | 0.160 |
Why?
|
| Psychometrics | 2 | 2020 | 337 | 0.160 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2020 | 28 | 0.160 |
Why?
|
| Cohort Studies | 3 | 2023 | 3054 | 0.160 |
Why?
|
| Multivariate Analysis | 3 | 2018 | 985 | 0.160 |
Why?
|
| Respiratory Tract Infections | 2 | 2019 | 110 | 0.160 |
Why?
|
| Hepatitis B, Chronic | 1 | 2020 | 34 | 0.160 |
Why?
|
| Evidence-Based Medicine | 6 | 2020 | 449 | 0.160 |
Why?
|
| Hemangioma | 1 | 2020 | 63 | 0.160 |
Why?
|
| Obesity | 5 | 2019 | 1018 | 0.160 |
Why?
|
| Complementary Therapies | 1 | 2020 | 53 | 0.150 |
Why?
|
| Antirheumatic Agents | 2 | 2012 | 59 | 0.150 |
Why?
|
| Infliximab | 6 | 2019 | 162 | 0.150 |
Why?
|
| Electronic Health Records | 1 | 2023 | 372 | 0.150 |
Why?
|
| Foundations | 4 | 2020 | 15 | 0.150 |
Why?
|
| CD11 Antigens | 5 | 2006 | 14 | 0.150 |
Why?
|
| Hepatitis C, Chronic | 1 | 2020 | 95 | 0.150 |
Why?
|
| Headache | 1 | 2019 | 75 | 0.150 |
Why?
|
| United States | 10 | 2020 | 7622 | 0.150 |
Why?
|
| Epitopes | 3 | 1998 | 254 | 0.140 |
Why?
|
| Remission Induction | 4 | 2020 | 738 | 0.140 |
Why?
|
| Digestive System Diseases | 1 | 1998 | 19 | 0.140 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2018 | 29 | 0.140 |
Why?
|
| Body Surface Area | 1 | 2018 | 36 | 0.140 |
Why?
|
| Fingers | 2 | 1996 | 53 | 0.140 |
Why?
|
| Social Class | 1 | 2018 | 141 | 0.130 |
Why?
|
| Disease Progression | 3 | 2013 | 1531 | 0.130 |
Why?
|
| Epidermolysis Bullosa Acquisita | 1 | 1997 | 2 | 0.130 |
Why?
|
| Photopheresis | 1 | 1997 | 12 | 0.130 |
Why?
|
| Linear Models | 1 | 2018 | 413 | 0.130 |
Why?
|
| Physician's Role | 1 | 2019 | 176 | 0.130 |
Why?
|
| Fractures, Spontaneous | 1 | 2017 | 16 | 0.130 |
Why?
|
| Multicenter Studies as Topic | 3 | 2006 | 181 | 0.120 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1997 | 100 | 0.120 |
Why?
|
| Patient Preference | 1 | 2018 | 125 | 0.120 |
Why?
|
| Inflammation | 3 | 2025 | 1050 | 0.120 |
Why?
|
| Pain | 2 | 2018 | 414 | 0.120 |
Why?
|
| Absenteeism | 1 | 2016 | 10 | 0.120 |
Why?
|
| Inpatients | 2 | 2016 | 345 | 0.120 |
Why?
|
| Clonazepam | 1 | 1996 | 2 | 0.120 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 543 | 0.120 |
Why?
|
| Lymphocyte Activation | 5 | 2003 | 797 | 0.120 |
Why?
|
| Efficiency | 1 | 2016 | 39 | 0.120 |
Why?
|
| GABA Modulators | 1 | 1996 | 8 | 0.120 |
Why?
|
| Drug Therapy, Combination | 4 | 2019 | 759 | 0.120 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 1996 | 20 | 0.120 |
Why?
|
| Combined Modality Therapy | 5 | 2020 | 1723 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 1997 | 2544 | 0.120 |
Why?
|
| Mycosis Fungoides | 1 | 1996 | 30 | 0.120 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2015 | 10 | 0.120 |
Why?
|
| Fluoxetine | 1 | 1996 | 41 | 0.120 |
Why?
|
| Child | 7 | 2024 | 7355 | 0.120 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2015 | 4 | 0.110 |
Why?
|
| Osteoporosis | 1 | 2017 | 129 | 0.110 |
Why?
|
| Sarcoma, Kaposi | 1 | 1995 | 17 | 0.110 |
Why?
|
| Administration, Cutaneous | 3 | 2020 | 61 | 0.110 |
Why?
|
| Patient Satisfaction | 3 | 2014 | 484 | 0.110 |
Why?
|
| Astrocytes | 3 | 2002 | 141 | 0.110 |
Why?
|
| Doxorubicin | 1 | 1995 | 284 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2017 | 585 | 0.100 |
Why?
|
| Acitretin | 3 | 2020 | 4 | 0.100 |
Why?
|
| Coronary Artery Disease | 2 | 2008 | 375 | 0.100 |
Why?
|
| Hospitalization | 2 | 2016 | 937 | 0.100 |
Why?
|
| Sickness Impact Profile | 1 | 2013 | 28 | 0.100 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 86 | 0.100 |
Why?
|
| Hospital Mortality | 3 | 2016 | 482 | 0.100 |
Why?
|
| Retrospective Studies | 4 | 2023 | 10164 | 0.100 |
Why?
|
| Disability Evaluation | 1 | 2013 | 171 | 0.090 |
Why?
|
| Wound Healing | 2 | 2006 | 373 | 0.090 |
Why?
|
| Rheumatic Diseases | 1 | 2012 | 30 | 0.090 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2011 | 22 | 0.090 |
Why?
|
| Acute Disease | 2 | 2023 | 841 | 0.090 |
Why?
|
| Cross-Sectional Studies | 4 | 2018 | 1847 | 0.090 |
Why?
|
| Safety Management | 1 | 2011 | 51 | 0.090 |
Why?
|
| Long-Term Care | 1 | 2011 | 63 | 0.080 |
Why?
|
| SEER Program | 1 | 2011 | 235 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 486 | 0.080 |
Why?
|
| Keratinocytes | 2 | 2009 | 146 | 0.080 |
Why?
|
| Academies and Institutes | 2 | 2020 | 33 | 0.080 |
Why?
|
| Global Health | 2 | 2012 | 208 | 0.080 |
Why?
|
| Opportunistic Infections | 3 | 2018 | 57 | 0.080 |
Why?
|
| Health Status Indicators | 2 | 2007 | 101 | 0.070 |
Why?
|
| Depressive Disorder | 1 | 2010 | 225 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2024 | 3829 | 0.070 |
Why?
|
| Drug Approval | 1 | 2009 | 68 | 0.070 |
Why?
|
| Comorbidity | 3 | 2019 | 1007 | 0.070 |
Why?
|
| Cytokines | 2 | 2003 | 863 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2009 | 142 | 0.070 |
Why?
|
| Placebo Effect | 1 | 2008 | 35 | 0.070 |
Why?
|
| Logistic Models | 2 | 2016 | 1243 | 0.070 |
Why?
|
| Dyslipidemias | 2 | 2019 | 108 | 0.070 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 383 | 0.070 |
Why?
|
| B7-1 Antigen | 2 | 1998 | 75 | 0.070 |
Why?
|
| CD2 Antigens | 1 | 2007 | 22 | 0.060 |
Why?
|
| Computer Graphics | 2 | 2003 | 100 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2007 | 213 | 0.060 |
Why?
|
| Immune System | 1 | 2007 | 101 | 0.060 |
Why?
|
| Etretinate | 1 | 2006 | 4 | 0.060 |
Why?
|
| Syndrome | 2 | 1998 | 437 | 0.060 |
Why?
|
| Animals | 7 | 2013 | 28155 | 0.060 |
Why?
|
| Candidiasis | 2 | 2016 | 39 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 1 | 2007 | 281 | 0.060 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2007 | 147 | 0.060 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2007 | 175 | 0.060 |
Why?
|
| Biopsy | 2 | 2007 | 1175 | 0.060 |
Why?
|
| Vaccination | 1 | 2007 | 304 | 0.060 |
Why?
|
| Cell Count | 1 | 2005 | 197 | 0.060 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2005 | 21 | 0.060 |
Why?
|
| Neutropenia | 2 | 2016 | 209 | 0.060 |
Why?
|
| Surveys and Questionnaires | 4 | 2016 | 2802 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2018 | 4560 | 0.060 |
Why?
|
| Neoplasms | 4 | 2019 | 3169 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2005 | 2495 | 0.060 |
Why?
|
| Mice, SCID | 1 | 2005 | 271 | 0.060 |
Why?
|
| Fatigue | 1 | 2006 | 181 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2007 | 260 | 0.050 |
Why?
|
| Patient Selection | 1 | 2008 | 690 | 0.050 |
Why?
|
| Interferon-gamma | 4 | 2002 | 460 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 371 | 0.050 |
Why?
|
| Skin Transplantation | 1 | 2005 | 191 | 0.050 |
Why?
|
| Nova Scotia | 1 | 2003 | 2 | 0.050 |
Why?
|
| Bacteriophage phi X 174 | 1 | 2003 | 2 | 0.050 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2003 | 18 | 0.050 |
Why?
|
| Tetanus Toxoid | 1 | 2003 | 10 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2003 | 63 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 2 | 2002 | 145 | 0.050 |
Why?
|
| Registries | 2 | 2020 | 990 | 0.050 |
Why?
|
| Acne Vulgaris | 1 | 2024 | 33 | 0.050 |
Why?
|
| Dermatitis | 1 | 2024 | 34 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2003 | 98 | 0.050 |
Why?
|
| Life Style | 2 | 2019 | 183 | 0.050 |
Why?
|
| Eye Diseases | 2 | 2002 | 58 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2004 | 194 | 0.050 |
Why?
|
| Skin, Artificial | 1 | 2002 | 7 | 0.050 |
Why?
|
| Drug Design | 1 | 2003 | 133 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2002 | 988 | 0.050 |
Why?
|
| Self Report | 2 | 2015 | 328 | 0.050 |
Why?
|
| Length of Stay | 2 | 2016 | 828 | 0.050 |
Why?
|
| Forecasting | 1 | 2003 | 293 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2023 | 179 | 0.050 |
Why?
|
| Stroke | 1 | 2011 | 1079 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2019 | 2479 | 0.040 |
Why?
|
| Illinois | 1 | 2003 | 520 | 0.040 |
Why?
|
| Pancytopenia | 1 | 2002 | 18 | 0.040 |
Why?
|
| Risk Factors | 4 | 2008 | 5899 | 0.040 |
Why?
|
| Vitamin D | 2 | 2018 | 272 | 0.040 |
Why?
|
| Nausea | 1 | 2002 | 93 | 0.040 |
Why?
|
| Spondylitis, Ankylosing | 2 | 2012 | 30 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2002 | 200 | 0.040 |
Why?
|
| Arthritis, Juvenile | 2 | 2012 | 32 | 0.040 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2002 | 104 | 0.040 |
Why?
|
| Infant | 2 | 2019 | 3220 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 173 | 0.040 |
Why?
|
| Collagen | 1 | 2002 | 304 | 0.040 |
Why?
|
| California | 2 | 2015 | 158 | 0.040 |
Why?
|
| Sunlight | 1 | 2001 | 27 | 0.040 |
Why?
|
| Interferon Type I | 1 | 2021 | 164 | 0.040 |
Why?
|
| Pemphigus, Benign Familial | 1 | 2000 | 1 | 0.040 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2011 | 20 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2005 | 557 | 0.040 |
Why?
|
| Pneumonia | 1 | 2002 | 193 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2002 | 436 | 0.040 |
Why?
|
| Anthralin | 1 | 2019 | 1 | 0.040 |
Why?
|
| Coal Tar | 1 | 2019 | 1 | 0.040 |
Why?
|
| Nicotinic Acids | 1 | 2019 | 8 | 0.040 |
Why?
|
| Retinoids | 1 | 2019 | 18 | 0.040 |
Why?
|
| Demography | 1 | 2020 | 189 | 0.040 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2000 | 53 | 0.040 |
Why?
|
| Antigens, CD | 2 | 2002 | 476 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2016 | 1006 | 0.040 |
Why?
|
| Hemangioendothelioma | 1 | 1999 | 9 | 0.040 |
Why?
|
| Calcineurin Inhibitors | 1 | 2019 | 53 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2019 | 83 | 0.040 |
Why?
|
| Lymphoma | 2 | 2008 | 247 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2020 | 119 | 0.040 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2019 | 19 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 159 | 0.040 |
Why?
|
| Mice | 5 | 2005 | 12269 | 0.040 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2019 | 26 | 0.040 |
Why?
|
| Foot Dermatoses | 1 | 2018 | 3 | 0.040 |
Why?
|
| Nails | 1 | 2018 | 11 | 0.040 |
Why?
|
| Canada | 2 | 2010 | 194 | 0.040 |
Why?
|
| Scalp Dermatoses | 1 | 2018 | 10 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2001 | 457 | 0.030 |
Why?
|
| Pancreatic Diseases | 1 | 1998 | 58 | 0.030 |
Why?
|
| Apoptosis | 2 | 2007 | 1721 | 0.030 |
Why?
|
| Income | 1 | 2018 | 87 | 0.030 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2019 | 106 | 0.030 |
Why?
|
| Myelin Sheath | 1 | 1998 | 66 | 0.030 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 1998 | 66 | 0.030 |
Why?
|
| Educational Status | 1 | 2018 | 197 | 0.030 |
Why?
|
| Isotretinoin | 1 | 1997 | 20 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1997 | 68 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2019 | 379 | 0.030 |
Why?
|
| Overweight | 1 | 2018 | 120 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1997 | 187 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 1998 | 229 | 0.030 |
Why?
|
| Ovalbumin | 1 | 1997 | 102 | 0.030 |
Why?
|
| Basement Membrane | 1 | 1997 | 57 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2010 | 884 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2018 | 122 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 1999 | 366 | 0.030 |
Why?
|
| Presenteeism | 1 | 2016 | 1 | 0.030 |
Why?
|
| Health Surveys | 1 | 2017 | 241 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 80 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 2019 | 315 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 174 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 206 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 1997 | 129 | 0.030 |
Why?
|
| Georgia | 1 | 2015 | 37 | 0.030 |
Why?
|
| Colorado | 1 | 2015 | 39 | 0.030 |
Why?
|
| Washington | 1 | 2015 | 49 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 1996 | 149 | 0.030 |
Why?
|
| Foot | 1 | 1995 | 56 | 0.030 |
Why?
|
| Liposomes | 1 | 1995 | 98 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2016 | 142 | 0.030 |
Why?
|
| Janus Kinase 3 | 1 | 2014 | 9 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1995 | 67 | 0.030 |
Why?
|
| Single-Blind Method | 2 | 2006 | 159 | 0.030 |
Why?
|
| Drug Carriers | 1 | 1995 | 88 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 1997 | 444 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1995 | 401 | 0.030 |
Why?
|
| Hepatitis, Viral, Human | 2 | 2009 | 20 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 711 | 0.030 |
Why?
|
| Hand | 1 | 1995 | 143 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2014 | 233 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 1994 | 203 | 0.030 |
Why?
|
| Eye Neoplasms | 1 | 1993 | 25 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 624 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2015 | 347 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2008 | 811 | 0.020 |
Why?
|
| Macrophages | 2 | 2007 | 610 | 0.020 |
Why?
|
| Patient Participation | 1 | 2015 | 229 | 0.020 |
Why?
|
| Hypertension | 1 | 2019 | 757 | 0.020 |
Why?
|
| Skin Diseases, Infectious | 1 | 2012 | 8 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 1524 | 0.020 |
Why?
|
| Focus Groups | 1 | 2013 | 184 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2012 | 31 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1996 | 1546 | 0.020 |
Why?
|
| Brain | 1 | 2002 | 2391 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2715 | 0.020 |
Why?
|
| Health Status | 1 | 2013 | 377 | 0.020 |
Why?
|
| Case Management | 1 | 2011 | 29 | 0.020 |
Why?
|
| Cognition | 1 | 2015 | 627 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 657 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1996 | 1448 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 1229 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 259 | 0.020 |
Why?
|
| Reference Values | 1 | 2010 | 608 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2002 | 171 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2009 | 80 | 0.020 |
Why?
|
| Ultraviolet Therapy | 1 | 2008 | 17 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 1321 | 0.020 |
Why?
|
| Survival Rate | 2 | 2005 | 1948 | 0.020 |
Why?
|
| Nasopharyngitis | 1 | 2008 | 2 | 0.020 |
Why?
|
| Tuberculin Test | 1 | 2007 | 9 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2007 | 15 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2007 | 91 | 0.020 |
Why?
|
| Sweden | 1 | 2007 | 45 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 1993 | 813 | 0.020 |
Why?
|
| Antibodies, Antinuclear | 1 | 2007 | 94 | 0.020 |
Why?
|
| Medical Records | 1 | 2007 | 121 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 204 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2007 | 224 | 0.020 |
Why?
|
| International Cooperation | 1 | 2007 | 133 | 0.020 |
Why?
|
| Physical Examination | 1 | 2007 | 144 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2009 | 352 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2008 | 237 | 0.020 |
Why?
|
| Ontario | 1 | 2006 | 31 | 0.020 |
Why?
|
| Burn Units | 1 | 2005 | 21 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 2002 | 2850 | 0.010 |
Why?
|
| Fibrosis | 1 | 2006 | 230 | 0.010 |
Why?
|
| Hospitals, University | 1 | 2005 | 188 | 0.010 |
Why?
|
| Self-Assessment | 1 | 2005 | 45 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 225 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2006 | 347 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 306 | 0.010 |
Why?
|
| Buttocks | 1 | 2003 | 10 | 0.010 |
Why?
|
| Smoking | 1 | 2008 | 648 | 0.010 |
Why?
|
| Scrotum | 1 | 2003 | 14 | 0.010 |
Why?
|
| Thigh | 1 | 2003 | 41 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 302 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2007 | 536 | 0.010 |
Why?
|
| Biomedical Engineering | 1 | 2002 | 21 | 0.010 |
Why?
|
| Mohs Surgery | 1 | 2002 | 27 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2007 | 438 | 0.010 |
Why?
|
| Myelin Proteolipid Protein | 1 | 2002 | 1 | 0.010 |
Why?
|
| Hybridomas | 1 | 2002 | 61 | 0.010 |
Why?
|
| Pregnancy | 1 | 2009 | 3147 | 0.010 |
Why?
|
| Clone Cells | 1 | 2002 | 219 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2002 | 170 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2002 | 244 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2002 | 174 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2002 | 149 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2002 | 373 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 1799 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2007 | 1621 | 0.010 |
Why?
|
| Sweat Glands | 1 | 2000 | 6 | 0.010 |
Why?
|
| Pain, Postoperative | 1 | 2002 | 276 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2002 | 470 | 0.010 |
Why?
|
| HIV Infections | 1 | 2009 | 961 | 0.010 |
Why?
|
| Injections | 1 | 2000 | 124 | 0.010 |
Why?
|
| Axilla | 1 | 2000 | 109 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1999 | 280 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1999 | 315 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1999 | 399 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1999 | 367 | 0.010 |
Why?
|
| Cell Line | 1 | 2002 | 2464 | 0.010 |
Why?
|
| Adoptive Transfer | 1 | 1998 | 172 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 693 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 1028 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1999 | 824 | 0.010 |
Why?
|
| B7-2 Antigen | 1 | 1997 | 42 | 0.010 |
Why?
|
| Abatacept | 1 | 1997 | 87 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 1997 | 124 | 0.010 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 1996 | 9 | 0.010 |
Why?
|
| CTLA-4 Antigen | 1 | 1997 | 144 | 0.010 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 1996 | 44 | 0.010 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1996 | 110 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 1998 | 502 | 0.010 |
Why?
|
| Gene Expression | 1 | 1999 | 1301 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1997 | 1101 | 0.010 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1996 | 242 | 0.010 |
Why?
|
| Vitreous Body | 1 | 1993 | 54 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1997 | 2012 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1997 | 2910 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1997 | 2026 | 0.010 |
Why?
|